ArticleBiology direct2026
ZNF750 suppresses esophageal squamous cell carcinoma by maintaining epithelial barrier-driven mucosal immune homeostasis.
Article in Biology direct, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundRecent studies have shown that zinc finger protein 750 (ZNF750), a key tumor suppressor in esophageal squamous cell carcinoma (ESCC), is associated with defective epithelial differentiation. At the same time, mucosal immune dysfunction is increasingly recognized as a key factor in the development of ESCC. Exploring the role of ZNF750 in regulating the mucosal immune microenvironment provides a new perspective on its tumor suppression mechanism.
resultsBy integrating analyses across multiple platforms, including bulk transcriptomics (TCGA, GTEx, GEO), and single-cell RNA sequencing (scRNA-seq), we demonstrate that ZNF750 is significantly downregulated in ESCC, with high expression serving as an independent prognostic marker for longer survival. Mechanistically, ZNF750 suppresses ESCC progression by maintaining epithelial barrier–driven mucosal immune homeostasis. WGCNA analyses indicate that ZNF750-high tumors are enriched in mucosal immune response and antimicrobial defense pathways. Experimental validation reveals that ZNF750 positively regulates DEFB4A (human beta-defensin-2), a key antimicrobial peptide. In addition, ZNF750 fosters an anti-tumor immune environment by recruiting neutrophils and suppressing pro-tumor M2 macrophages, a finding corroborated by clinical validation showing that high ZNF750 expression correlates with elevated neutrophil infiltration. Clinical validation confirms that high ZNF750 expression correlates with elevated neutrophil infiltration. Additionally, ZNF750 expression is linked to a healthy mucosal microbiota and the exclusion of pro-carcinogenic bacteria. Single-cell analysis shows that ZNF750-expressing epithelial cells maintain barrier integrity and coordinate immune surveillance through MHC-I/II signaling. Loss of ZNF750 may drive mucosal immune dysregulation, where the immune network is replaced by a pre-fibrotic immunosuppressive niche dominated by cancer-associated fibroblasts (CAFs).
conclusionsCollectively, our findings identify ZNF750 as a key molecular link between epithelial barrier integrity and mucosal immune surveillance in ESCC, highlighting restoration of ZNF750-mediated barrier immunity as a potential therapeutic strategy for ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.